Desenvolvimento de um candidato a medicamento inovador para desacelerar a progressão da doença de Parkinson.

As mentioned in the description section, we established 3 aims for SlowPD: Aim1 - To characterize in vivo the efficacy of N1inh-IL when administered via subcutaneous, oral, rectal, and intravenous (i.v.) routes. Thorough characterization of different administration routes is crucial for optimizing therapy, ensuring safety and compliance, regulatory approval, and bringing new drugs to market. Understanding the advantages and limitations of each route facilitates the development of more effective and patient-friendly formulations. Having established N1inh-IL's ability to cross the blood-brain barrier (BBB), we have characterized its pharmacokinetic/pharmacodynamic properties and 14-day safety via i.v. route, and its therapeutic efficacy via intracerebroventricular and intranasal routes. Aim 1 involves evaluating N1inh-IL efficacy via subcutaneous, oral, rectal, and intravenous routes, which will complement our current knowledge on its effect when using the intranasal and i.v. route and will support the next pipeline steps of DMPK and long-term safety studies conducted by WuXi App Tec. Aim 2 - Characterize N1inh-IL efficacy in stem cell-derived human neurons. Evaluating the efficacy of a drug candidate in stem cell-derived human neurons holds immense importance in pharmaceutical research and development, particularly in the context of neurological disorders. This is particularly important because the relevance to human physiology testing drug candidates in these cells provides a more physiologically relevant model than traditional animal models or non-human cell lines. This enhances the translatability of preclinical findings to human clinical trials, potentially reducing the risk of unforeseen adverse effects or lack of efficacy in humans. This is a crucial aim for our drug candidate pipeline since evaluating N1inh-IL efficacy in stem cell-derived human neurons will increase the likelihood of successful translation to clinical trials. Aims 3 - Project translation, management and dissemination. The success of SlowPD is not solely determined by the quality of the proposed project but also by effective project translation, management, and dissemination. Herein we aim to keep a good project translation to ensure that the goals and objectives outlined in the proposal are effectively translated into actionable plans and strategies. This has involved breaking the project aims into manageable tasks, to which we have allocated the right team and resources and established clear timelines and milestones. By aligning the project activities with the proposed objectives, we can maximize the chances of achieving meaningful outcomes and meeting the expectations of funding agencies and stakeholders. We will optimize resource utilization, monitor timely progress and quality control, and create a robust dissemination and communication plan. With this aim and by effectively translating project goals into actionable plans, optimizing resource utilization, monitoring progress, ensuring quality control, disseminating results, and fostering accountability and transparency, we intend to maximize the impact of the project outcomes to promote its commercialization and contribute to scientific advancement and societal benefit.